Literature DB >> 17678959

Relevance of high-mobility group protein box 1 to neurodegeneration.

Silvia Fossati1, Alberto Chiarugi.   

Abstract

High-mobility group protein box 1 (HMGB1), also know as amphoterin, is a nonhistone nuclear protein with well-established functions in gene transcription and homeostasis regulation into the cell nucleus. Interestingly, the protein can be passively released in the extracellular space during necrosis, whereas retained into the nucleus by cells undergoing apoptosis. Also, immune cells actively release HMGB1 on stimulation. Emerging evidence undoubtedly demonstrates that extracellular HMGB1 engages membrane receptors on different cells signaling proliferation, differentiation, cytoprotection, as well as immune activation. Consistently, numerous reports point to HMGB1 as a novel player in disease pathogenesis in peripheral organs. This chapter provides an appraisal of the emerging roles of HMGB1 in neuropathology and the neuroinflammatory response, highlighting the relevance of HMGB1-blocking agents as innovative therapeutic tools to be harnessed for neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17678959     DOI: 10.1016/S0074-7742(07)82007-1

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  5 in total

Review 1.  Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting.

Authors:  Georgina S Butler; Christopher M Overall
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

2.  Rpl30 and Hmgb1 are required for neurulation in golden hamster.

Authors:  Li Yu; Ying Jun Guan; Yingmao Gao; Xin Wang
Journal:  Int J Neurosci       Date:  2009       Impact factor: 2.292

3.  High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.

Authors:  Arafat Hussein Al-Dujaili; Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Michael Maes
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

Review 4.  Rational modulation of the innate immune system for neuroprotection in ischemic stroke.

Authors:  Diana Amantea; Giuseppe Micieli; Cristina Tassorelli; María I Cuartero; Iván Ballesteros; Michelangelo Certo; María A Moro; Ignacio Lizasoain; Giacinto Bagetta
Journal:  Front Neurosci       Date:  2015-04-29       Impact factor: 4.677

Review 5.  An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.

Authors:  Andrea Terron; Anna Bal-Price; Alicia Paini; Florianne Monnet-Tschudi; Susanne Hougaard Bennekou; Marcel Leist; Stefan Schildknecht
Journal:  Arch Toxicol       Date:  2017-12-05       Impact factor: 5.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.